TABLE 1.
Dual PI3K/mTOR inhibitors in current clinical trials that listed in the article.
| Inhibitor | Conditions | Phase | Status | Time period | Intervention model | NCT number | References |
|---|---|---|---|---|---|---|---|
| Samotolisib | Advanced malignant solid neoplasm | 2 | Recruiting | 24 July 2017 to 30 September 2027 | Parallel assignment | NCT03155620 | Azaro et al. (2021) |
| Ann Arbor stage III non-hodgkin lymphoma | |||||||
| Ann Arbor stage IV non-hodgkin lymphoma (and 42 more) | |||||||
| Endometrial cancer recurrent endometrial cancer | 2 | Active, not recruiting | September 2015 to September 2022 | Single group assignment (Samotolisib) | NCT02549989 | ||
| Triple negative breast cancer | 2 | Recruiting | 5 September 2019 to August 2022 | Single group assignmen (1. samotolisib 2. Prexasertib) | NCT04032080 | ||
| Breast neoplasms | 1 | Active, not recruiting | 10 March 2014 to 28 October 2022 | Parallel assignment | NCT02057133 | ||
| Solid tumor breast cancer colon cancer cholangiocarcinoma soft tissue sarcoma | 1b | Completed | 4 November 2016 to 13 February 2020 | Parallel assignment | NCT02784795 | ||
| Apitolisib | Prostate cancer | 1/2 | Active, not recruiting | 11 January 2012 to 30 April 2021* | Parallel assignment | NCT01485861 | |
| Paxalisib | Primary central nervous system lymphoma non-hodgkin lymphoma of extranodal site | 2 | Recruiting | 1 June 2021 to 1 May 2024 | Single group assignment (Paxalisib) | NCT04906096 | |
| Glioblastoma, adult | 2 | Active, not recruiting | 15 May 2018 to 30 December 2020* | Single group assignment (Paxalisib) | NCT03522298 | ||
| CDK gene mutation metastatic malignant neoplasm in the brain metastatic malignant solid neoplasm (and 3 more) | 2 | Recruiting | 15 August 2019 to June 2025 | Parallel assignment | NCT03994796 | ||
| Glioblastoma | 2/3 | Recruiting | 30 July 2019 to June 2024 | Sequential assignment | NCT03970447 | ||
| Brain metastases leptomeningeal metastasis | 1 | Recruiting | 6 December 2019 to December 2022 | Single Group assignment | NCT04192981 | ||
| Brain and central nervous system tumours | 1 | Active, not recruiting | 19 November 2018 to June 2024 | Parallel assignment | NCT03696355 | ||
| Breast cancer | 2 | Recruiting | 11 February 2019 to 30 November 2025 | Parallel assignment (1. Trastuzumab, 2. Paxalisib) | NCT03765983 | ||
| Gedatolisib | HER2-positive breast cancer metastatic breast cancer | 2 | Recruiting | 3 December 2019 to December 2021 | Single group assignment (1. Trastuzumab biosimilars (Herzuma), 2. Gedatolisib) | NCT03698383 | |
| TNBC - Triple-negative breast cancer | 1/2 | Recruiting | 17 April 2019 to May 2022 | Single group assignment (1. Gedatolisib 2.Talazoparib) | NCT03911973 | ||
| Lung cancer squamous Cell Solid tumours head and neck cancer pancreatic cancer | 1 | Recruiting | 28 February 2017 to January 2023 | Single group assignment (1. Palbociclib 2. Gedatolisib) | NCT03065062 | ||
| Breast cancer | 1 | Active, not recruiting | January 2016 to September 2020* | Single group assignment | NCT02626507 | ||
| Triple negative breast cancer metastatic breast cancer | 1 | Completed | 19 January 2018 to 27 May 2020 | Sequential assignment (1.Gedatolisib 2.PTK7-ADC) | NCT03243331 | ||
| Breast cancer | 1b | Completed | 14 June 2016 to 11 June 2022 | Parallel assignment | NCT02684032 | Forero et al. (2018) | |
| Neoplasm | 1b | Completed | September 10, to 2013 8 January 2020 | Single group assignment | NCT01920061 | ||
| Bimiralisib | HNSCC | 2 | Terminated | 25 January 2019 to 5 August 2020 | Single group assignment | NCT03740100 | Johnson et al. (2020) |
| Lymphoma, Malignant | 2 | Completed | May 2015 to 11 September 2018 | Single group assignment | NCT02249429 | ||
| Primary central nervous system lymphoma | 2 | Completed | 12 November 2015 to 12 January 2018 | Single group assignment | NCT02669511 |
The data were collected from https://clinicaltrials.gov (Last accessed 23 Mar 2022).